Dataset Information

Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.

ABSTRACT:

Objectives

To identify patient demographics and characteristics associated with compliance to statin therapy after switching from branded to generic agents

Design

Retrospective cohort study using electronic health records and pharmacy claims data from Sutter Health's ambulatory-care medical network

Patients

Managed-care beneficiaries, ? 18 years of age, who were switched from branded to generic statins between 1 January 2003 and 31 December 2012 MAIN MEASURES: Compliance was calculated as days of therapy dispensed divided by days from first to last generic prescription fill over 6 months, and was defined as a medication possession ratio ? 0.80. We used multivariable logistic regression to assess factors associated with compliance. Adjusted ORs and 95% CI were generated.

Key results

We identified 5,156 patients who were switched from branded to generic statins; 73% of patients were compliant in the 6 months after switching. After statistical adjustment, higher compliance was associated with each 10-year increase in age (OR: 1.13; 95% CI: 1.07, 1.19; p?ConclusionsThe majority of patients switched from branded to generic agents were compliant with therapy in the first 6 months after switching. The potential for non-compliance to generic statin therapy, particularly among younger or Hispanic patients or when dose/potency changes are made, should be considered prior to switching. For these patients, counseling or close monitoring may be required to optimize generic interchange.

SUBMITTER: Romanelli RJ

PROVIDER: S-EPMC4175637 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.

Romanelli Robert J RJ Segal Jodi B JB

Journal of general internal medicine 20140624 10

<h4>Objectives</h4>To identify patient demographics and characteristics associated with compliance to statin therapy after switching from branded to generic agents<h4>Design</h4>Retrospective cohort study using electronic health records and pharmacy claims data from Sutter Health's ambulatory-care medical network<h4>Patients</h4>Managed-care beneficiaries, ≥ 18 years of age, who were switched from branded to generic statins between 1 January 2003 and 31 December 2012 MAIN MEASURES: Compliance wa ...[more]

PMID: 24957381

Similar Datasets

Project description:Low adherence to bisphosphonate therapy is associated with increased fracture risk. Factors associated with discontinuation of osteoporosis medications have not been studied in-depth. This study assessed medication discontinuation and switching patterns among Medicare beneficiaries who were new users of bisphosphonates and evaluated factors possibly associated with discontinuation.We identified patients initiating bisphosphonate treatment using a 5% random sample of Medicare beneficiaries with at least 24 months of traditional fee-for-service and part D drug coverage from 2006 through 2009. We classified medication status at the end of follow-up as: continued original bisphosphonate, discontinued without switching or restarting, restarted the same drug after a treatment gap (? 90 days), or switched to another anti-osteoporosis medication. We conducted logistic regression analyses to identify baseline characteristics associated with discontinuation and a case-crossover analysis to identify factors that precipitate discontinuation.Of 21,452 new users followed respectively for 12 months, 44% continued their original therapy, 36% discontinued without switching or restarting, 8% restarted the same drug after a gap greater than 90 days, and 11% switched to another anti-osteoporosis medication. Factors assessed during the 12-month period before initiation were weakly associated with discontinuation. Several Factors measured during follow-up were associated with discontinuation, including more physician visits, hospitalization, having a dual-energy X-ray absorptiometry test, higher Charlson comorbidity index scores, higher out-of-pocket drug payments, and upper gastrointestinal problems. Patterns were similar for 4,738 new users followed for 30 months.Among new bisphosphonates users, switching within and across drug classes and extended treatment gaps are common. Robust definitions and time-varying considerations should be considered to characterize medication discontinuation more accurately.

Dataset Information

Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.

Objectives

Design

Patients

Key results

Publications

Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure